JP2004529914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529914A5 JP2004529914A5 JP2002578974A JP2002578974A JP2004529914A5 JP 2004529914 A5 JP2004529914 A5 JP 2004529914A5 JP 2002578974 A JP2002578974 A JP 2002578974A JP 2002578974 A JP2002578974 A JP 2002578974A JP 2004529914 A5 JP2004529914 A5 JP 2004529914A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- amino
- alkoxy
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, monosubstituted amino Chemical group 0.000 claims 22
- 239000003112 inhibitor Substances 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 12
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 230000030558 renal glucose absorption Effects 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000003287 optical effect Effects 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004001 thioalkyl group Chemical group 0.000 claims 4
- 125000005403 thiohaloalkoxy group Chemical group 0.000 claims 4
- GMYFQAHYWIYNES-PFKOEMKTSA-N 3-(1-benzofuran-5-yl)-1-[2-hydroxy-4-methyl-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]propan-1-one Chemical compound C=1C(C)=CC(O)=C(C(=O)CCC=2C=C3C=COC3=CC=2)C=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMYFQAHYWIYNES-PFKOEMKTSA-N 0.000 claims 2
- SLXTWXQUEZSSTJ-UHFFFAOYSA-N 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=2N=CC(=CC=2)C(O)=O)CC1 SLXTWXQUEZSSTJ-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 2
- 229940121908 Retinoid X receptor agonist Drugs 0.000 claims 2
- 108091006277 SLC5A1 Proteins 0.000 claims 2
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 2
- BXNCIERBDJYIQT-PRDVQWLOSA-N [(2r,3s,4s,5r,6s)-6-[2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OC)O[C@H]1OC1=CC(C)=CC(O)=C1C(=O)CCC1=CC=C(OC=C2)C2=C1 BXNCIERBDJYIQT-PRDVQWLOSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 229960001445 alitretinoin Drugs 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 229960002938 bexarotene Drugs 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical group C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 claims 2
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 claims 2
- 150000002009 diols Chemical group 0.000 claims 2
- 125000005640 glucopyranosyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 claims 2
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28147901P | 2001-04-04 | 2001-04-04 | |
| PCT/US2002/010542 WO2002080935A1 (en) | 2001-04-04 | 2002-04-03 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004529914A JP2004529914A (ja) | 2004-09-30 |
| JP2004529914A5 true JP2004529914A5 (https=) | 2005-12-22 |
| JP4590158B2 JP4590158B2 (ja) | 2010-12-01 |
Family
ID=23077475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002578974A Expired - Fee Related JP4590158B2 (ja) | 2001-04-04 | 2002-04-03 | グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6838442B2 (https=) |
| EP (1) | EP1392326B1 (https=) |
| JP (1) | JP4590158B2 (https=) |
| CN (1) | CN100384430C (https=) |
| AT (1) | ATE442148T1 (https=) |
| CA (1) | CA2443325C (https=) |
| DE (1) | DE60233655D1 (https=) |
| ES (1) | ES2331561T3 (https=) |
| MY (1) | MY148432A (https=) |
| TW (1) | TWI345978B (https=) |
| WO (1) | WO2002080935A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517993A (en) | 1999-08-31 | 2004-03-26 | Incyte San Diego Inc | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| IL157740A0 (en) | 2001-03-07 | 2004-03-28 | Incyte San Diego Inc | Heterocyclic derivatives and pharmaceutical compositions containing the same |
| US7265139B2 (en) | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
| WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
| AU2002352706A1 (en) * | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| KR20060105431A (ko) * | 2003-06-27 | 2006-10-11 | 닥터 레디스 리서치 파운데이션 | 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물 |
| CN1319956C (zh) * | 2003-09-12 | 2007-06-06 | 深圳市海粤门生物科技开发有限公司 | 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用 |
| KR20070011379A (ko) | 2004-03-17 | 2007-01-24 | 라스 미카엘 라르센 | 시각 사이클 억제에 의한 망막증의 예방 |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
| DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
| ES2541141T3 (es) * | 2008-01-31 | 2015-07-16 | Astellas Pharma Inc. | Composición farmacéutica para el tratamiento de las enfermedades del hígado graso |
| DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
| US8791077B2 (en) | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2010141690A2 (en) * | 2009-06-04 | 2010-12-09 | Dara Biosciences, Inc. | Indane analogs and use as pharmaceutical agents and process of making |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EA021983B1 (ru) | 2009-11-02 | 2015-10-30 | Пфайзер Инк. | Производные диоксабицикло[3.2.1]октан-2,3,4-триола |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA3114497A1 (en) | 2013-01-18 | 2014-07-24 | Cornell University | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
| EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
| EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
| AU2021202643B2 (en) | 2020-07-27 | 2023-02-02 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| EP4315350A1 (en) | 2021-04-01 | 2024-02-07 | AstraZeneca UK Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
| US20250108065A1 (en) | 2022-01-26 | 2025-04-03 | Astrazeneca Ab | Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin |
| EP4727530A2 (en) * | 2023-06-14 | 2026-04-22 | President and Fellows of Harvard College | Ion channel binders and uses thereof |
| WO2025125513A1 (en) | 2023-12-15 | 2025-06-19 | AstraZeneca Ireland Limited | Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US651003A (en) * | 1899-10-12 | 1900-06-05 | Solomon W Bates | Bicycle-pump. |
| JPH0253573A (ja) * | 1988-08-11 | 1990-02-22 | Nippon Riki Kk | ラチェットレンチの製造法 |
| US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
| US5731292A (en) * | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
| JP2906978B2 (ja) * | 1993-02-25 | 1999-06-21 | 田辺製薬株式会社 | 血糖降下剤 |
| US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| US5830873A (en) * | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
| JP2847695B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | 血糖降下剤 |
| ATE259227T1 (de) * | 1995-09-18 | 2004-02-15 | Ligand Pharm Inc | Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten |
| JP3065235B2 (ja) | 1995-11-07 | 2000-07-17 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
| JP3059088B2 (ja) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
| US5732199A (en) * | 1996-09-25 | 1998-03-24 | Behavior Tech Computer Corporation | Control method and device of scanner with built-in plug-and-play printer port |
| AU719726B2 (en) * | 1996-12-26 | 2000-05-18 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivatives and process for preparing the same |
| JP3055135B2 (ja) * | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| AU8799998A (en) | 1997-06-18 | 1999-01-04 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
| JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| NZ517993A (en) * | 1999-08-31 | 2004-03-26 | Incyte San Diego Inc | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| ATE264337T1 (de) | 1999-08-31 | 2004-04-15 | Kissei Pharmaceutical | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
| PE20010580A1 (es) | 1999-09-03 | 2001-05-25 | Takeda Chemical Industries Ltd | Composicion farmaceutica para tratar la diabetes |
| JP2001192375A (ja) * | 1999-10-29 | 2001-07-17 | Takeda Chem Ind Ltd | オキシイミノアルカン酸誘導体の結晶 |
| TW558554B (en) * | 1999-10-29 | 2003-10-21 | Takeda Chemical Industries Ltd | Crystals of oxyiminoalkanoic acid derivative |
| HK1045991B (en) * | 1999-11-10 | 2004-12-10 | Takeda Pharmaceutical Company Limited | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| MXPA03003870A (es) * | 2000-10-30 | 2004-08-12 | Johnson & Johnson | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. |
| PL209375B1 (pl) * | 2000-12-28 | 2011-08-31 | Kissei Pharmaceutical | Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej |
| WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
-
2002
- 2002-04-03 JP JP2002578974A patent/JP4590158B2/ja not_active Expired - Fee Related
- 2002-04-03 EP EP02715273A patent/EP1392326B1/en not_active Expired - Lifetime
- 2002-04-03 DE DE60233655T patent/DE60233655D1/de not_active Expired - Lifetime
- 2002-04-03 AT AT02715273T patent/ATE442148T1/de not_active IP Right Cessation
- 2002-04-03 ES ES02715273T patent/ES2331561T3/es not_active Expired - Lifetime
- 2002-04-03 US US10/115,725 patent/US6838442B2/en not_active Expired - Lifetime
- 2002-04-03 CA CA2443325A patent/CA2443325C/en not_active Expired - Lifetime
- 2002-04-03 WO PCT/US2002/010542 patent/WO2002080935A1/en not_active Ceased
- 2002-04-03 CN CNB02810482XA patent/CN100384430C/zh not_active Expired - Lifetime
- 2002-04-04 TW TW091106917A patent/TWI345978B/zh not_active IP Right Cessation
- 2002-04-04 MY MYPI20021222A patent/MY148432A/en unknown
-
2003
- 2003-02-24 US US10/372,517 patent/US20030195235A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,187 patent/US8183213B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529914A5 (https=) | ||
| JP2004529915A5 (https=) | ||
| CA2443325A1 (en) | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | |
| EP1522314B1 (en) | Remedies for diseases caused by vascular contraction or dilation | |
| KR100537843B1 (ko) | 아릴피페리디놀및아릴피페리딘유도체및이들을함유하는약제 | |
| JP4792974B2 (ja) | アゼチジン環化合物およびその医薬 | |
| AU754705B2 (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
| JP2005519083A5 (https=) | ||
| HU211607A9 (en) | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles | |
| CA2442917A1 (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators | |
| AU7291796A (en) | 8-azabicyclo{3.2.1}oct-2-ene derivatives, their preparation and use | |
| CN1690047A (zh) | 9－取代的二甲胺四环素化合物 | |
| WO2004089918A1 (ja) | 複素芳香５員環化合物及びその医薬用途 | |
| EP2448924B1 (fr) | Dérivés de pyrazoles, leur préparation et leur application en thérapeutique | |
| CN1039491C (zh) | 四氢咔唑化合物及其制备方法和应用 | |
| JP2013531070A (ja) | 置換３−フェニル−１，２，４−オキサジアゾール化合物 | |
| CA2533747A1 (en) | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors | |
| WO2004054560A1 (en) | Alpha-2-delta ligand to treat lower urinary tract symptoms | |
| WO2013047701A1 (ja) | フェニル誘導体 | |
| EP2408756A1 (en) | Alpha-(n-benzenesulfonamido)cycloalkyl derivatives | |
| US20030203945A1 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| CN1035939C (zh) | 取代的(芳烷基氨基苄基)氨基丙酰胺衍生物及其制备方法 | |
| JP2005505604A (ja) | ホスホロジエステラーゼｉｖ阻害剤の使用 | |
| WO2014157158A1 (ja) | フェニル誘導体 | |
| CA2613213A1 (fr) | Nouveaux composes de la famille des iminosucres, leurs utilisations pour le traitement de maladies lysosomales, ainsi que leur procede de preparation |